Anadys Pharmaceuticals, Inc. (ANDS) Stock Up More Than 90% After Release of Clinical Trial Results
Today before the opening bell, Anadys Pharmaceuticals, Inc. announced positive results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) and was very well-tolerated. The company anticipates reporting detailed data from multiple cohorts of the study at an upcoming medical conference. James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer, stated, "We are very pleased with the antiviral activity and safety of ANA598 at this first dose tested in the Phase Ib…